Shanghai Fosun Pharmaceutical Group Co (600196.SS) Stock Price
Shanghai Fosun Pharmaceutical Group Co Price
Shanghai Fosun Pharmaceutical Group Co (600196.SS) Stock | ISIN CNE000000X38. The current Shanghai Fosun Pharmaceutical Group Co stock price is 22.14 CNY (2026). Revenue is 44.24 B CNY. Net income is 4.15 B CNY. The P/E ratio is 14.26. Market capitalization is 59.12 B CNY. Shanghai Fosun Pharmaceutical Group Co operates in the Health sector.
Shanghai Fosun Pharmaceutical Group Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Shanghai Fosun Pharmaceutical Group Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Shanghai Fosun Pharmaceutical Group Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Shanghai Fosun Pharmaceutical Group Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Shanghai Fosun Pharmaceutical Group Co Price |
|---|
Shanghai Fosun Pharmaceutical Group Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Shanghai Fosun Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M CNY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M CNY) |
| NET INCOME (M CNY) |
| NET INCOME GROWTH (%) |
| DIVIDEND (CNY)DIV. (CNY) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Shanghai Fosun Pharmaceutical Group Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Shanghai Fosun Pharmaceutical Group Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Shanghai Fosun Pharmaceutical Group Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Shanghai Fosun Pharmaceutical Group Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Shanghai Fosun Pharmaceutical Group Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Shanghai Fosun Pharmaceutical Group Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Shanghai Fosun Pharmaceutical Group Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Shanghai Fosun Pharmaceutical Group Co business model & stock analysis
Shanghai Fosun Pharmaceutical Group Co SWOT Analysis
Strengths
Shanghai Fosun Pharmaceutical Group Co Ltd possesses several key strengths that give it a competitive advantage:
- 1. Strong Market Presence: Shanghai Fosun Pharmaceutical is a well-established player in the pharmaceutical industry with a significant market share in China and a growing presence in international markets.
- 2. Diverse Product Portfolio: The company offers a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and biopharmaceuticals, catering to various therapeutic areas.
- 3. Research and Development Capabilities: Shanghai Fosun Pharmaceutical has a dedicated research and development team focused on innovation, new drug discovery, and technology advancements.
- 4. Strong Financial Performance: The company has consistently delivered strong financial results, with steady revenue growth and healthy profit margins.
- 5. Strategic Partnerships: Shanghai Fosun Pharmaceutical has established collaborations with leading global pharmaceutical companies, enabling access to new markets, technologies, and expertise.
Weaknesses
Despite its strengths, Shanghai Fosun Pharmaceutical Group Co Ltd also faces certain weaknesses that need to be addressed:
- 1. Dependence on Domestic Market: The company is heavily reliant on the Chinese market, which exposes it to regulatory uncertainties, market fluctuations, and intense competition within the country.
- 2. Limited International Presence: While the company has made efforts to expand globally, its international operations remain relatively modest compared to its domestic business.
- 3. Product Quality Concerns: There have been instances of product quality issues in the past, which negatively impacted the company's reputation and raised concerns among consumers and regulatory authorities.
- 4. Integration Challenges: Shanghai Fosun Pharmaceutical has undergone several acquisitions and mergers, leading to integration challenges and potential disruptions in business operations.
Opportunities
Shanghai Fosun Pharmaceutical Group Co Ltd can capitalize on the following opportunities to further enhance its growth prospects:
- 1. Growing Healthcare Industry: The global healthcare market is expanding rapidly, presenting opportunities for Shanghai Fosun Pharmaceutical to expand its presence and penetrate new markets.
- 2. Aging Population and Chronic Diseases: With the increasing prevalence of chronic diseases and aging population, there is a rising demand for pharmaceutical products and healthcare services, creating a favorable market environment for the company.
- 3. Innovation and Technology Advancements: Advancements in healthcare technologies, such as precision medicine, gene therapy, and digital health solutions, open avenues for Shanghai Fosun Pharmaceutical to develop innovative products and services.
- 4. Strategic Collaborations: The company can explore strategic partnerships or collaborations with research institutions, universities, and other industry players to leverage expertise, access new technologies, and enhance its product pipeline.
Threats
Shanghai Fosun Pharmaceutical Group Co Ltd must be mindful of the following threats that could potentially impact its business:
- 1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous domestic and international players vying for market share, which may lead to price wars and margin squeeze.
- 2. Stringent Regulatory Environment: Compliance with stringent regulations and evolving regulatory frameworks adds complexities and costs to the company's operations.
- 3. Pricing Pressure: Government initiatives to control healthcare costs, pricing challenges in emerging markets, and reimbursement policies can exert pressure on the company's pricing and profit margins.
- 4. Intellectual Property Risks: Intellectual property theft, counterfeit products, and patent expirations pose risks to Shanghai Fosun Pharmaceutical's proprietary drugs and potential loss of market exclusivity.
Shanghai Fosun Pharmaceutical Group Co Eulerpool Fair Value
Shanghai Fosun Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio
Shanghai Fosun Pharmaceutical Group Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Shanghai Fosun Pharmaceutical Group Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Shanghai Fosun Pharmaceutical Group Co Dividend History
25 years of dividend payments
Shanghai Fosun Pharmaceutical Group Co dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Shanghai Fosun Pharmaceutical Group Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the Shanghai Fosun Pharmaceutical Group Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Shanghai Fosun Pharmaceutical Group Co shareholder structure
| % | Name |
|---|---|
33.32415% | |
1.45057% | |
1.38985% | |
0.86122% | |
0.78132% | |
0.59679% | |
0.50779% | |
0.39893% | |
0.3954% | |
0.38285% |
Shanghai Fosun Pharmaceutical Group Co Executives and Management Board
Mr. Kexin Wang
(59)Executive Co-Chairman of the Board · since 2011
Mr. Yifang Wu
(54)Executive Chairman of the Board · since 2016
Mr. Wenjie Zhang
(57)Executive President, Co-CEO - Innovative Drugs Division
Mr. Deyong Wen
(52)Chief Executive Officer, Executive Director · since 2016
Ms. Xiaohui Guan
(53)Executive Vice Chairman of the Board · since 2016
Frequently asked questions about Shanghai Fosun Pharmaceutical Group Co
The business model of Shanghai Fosun Pharmaceutical Group Co Ltd focuses on various aspects of the pharmaceutical industry. As a leading healthcare company, it engages in research and development, manufacturing, sales, and distribution of pharmaceutical products. Shanghai Fosun Pharmaceutical Group Co Ltd is committed to promoting innovation and improving the accessibility of healthcare products and services. It operates through segments such as pharmaceutical manufacturing, research and development, distribution and retail, and medical services. By leveraging its strong industry expertise and strategic partnerships, Shanghai Fosun Pharmaceutical Group Co Ltd aims to contribute to the advancement of healthcare and provide high-quality medical solutions to customers worldwide.
Shanghai Fosun Pharmaceutical Group Co stock
Shanghai Fosun Pharmaceutical Group Co Peer Group
Shanghai Fosun Pharmaceutical Group Co Ticker
Shanghai Fosun Pharmaceutical Group Co FIGI
All fundamentals and in-depth analysis of Shanghai Fosun Pharmaceutical Group Co
Our stock analysis for Shanghai Fosun Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Fosun Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.